A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients
Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy in mild to moderate COVID19 patients.
Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Hydroxychloroquine 400mg for the first day, then 200mg BID for nine days + Azithromycin 500mg daily for five days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symptomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if the result found positive. Time to the negative PCR and symptomatic recovery was measured for each group.
Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at a mean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of 9.33 days and were symptoms-free at 6.99 days. In group A 31.67% of patients expressed symptoms caused by medication, this was 46.43% in group B.
Conclusion: The combination therapy of Ivermectin-Doxycycline showed a trend towards superiority to the combination of Hydroxychloroquine-Azithromycin for mild to moderate COVID19 disease.
1.Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel Coronavirus (2019‐nCoV) in vitro. Cell Res 2020;30:269‐271. [CrossRef]
2. Weniger H, Organization WH Review of side effects and toxicity of chloroquine. 1979.https://apps.who.int/iris/handle/10665/65773. Accessed March thirty-first, 2020.
3. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of Hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2). Clin Infect Dis 2020. [CrossRef]
4. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020. [CrossRef]
5. Gautret P, Lagier J‐C, Parola P, et al. Hydroxychloroquine and Azithromycin as a treatment of COVID‐19: results of an open‐ label non‐randomized clinical trial. Int J Antimicrob Agents 2020.
6. Gautret P, Lagier J‐C, Parola P, Hoang VT, Meddeb L, Sevestre J. Clinical and microbiological effect of a combination of Hydroxychloroquine and Azithromycin in 80 COVID‐19 patients with at least a six‐day follow up: an observational study. Mediterr‐Infect.2020:101663 https://www.mediterranee-infection.com/ wp-content/uploads/2020/03/COVID-IHU-2-1.pdf [CrossRef]
7. Chan, Jasper F., et al. "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster." The Lancet, vol. 395, no. 10223, 2020, pp. 514-523. [CrossRef]
8. Li, Jinzhong, et al. "Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China." Virus Research, vol. 286, 2020, p. 198043. [CrossRef]
9. "Clinical findings in a group of patients infected with the 2019 novel Coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series." BMJ, 2020, p. m792. [CrossRef]
10. Meyerowitz, Eric A., et al. "Rethinking the role of hydroxychloroquine in the treatment of COVID‐19." The FASEB Journal, vol. 34, no. 5, 2020, pp., 6027-6037. [CrossRef]
11. Savarino, Andrea, and Mohammad Tarek. "Pharmacokinetic bases of the hydroxychloroquine response in COVID-19: implications for therapy and prevention." 2020.
12. Juurlink, David N. "Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection." Canadian Medical Association Journal, vol. 192, no. 17, 2020, pp. E450-E453. [CrossRef]
13. Accapezzato, Daniele, et al. "Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo." Journal of Experimental Medicine 2005;202:6:817-828. [CrossRef]
14. Ye, Qing, et al. "The pathogenesis and treatment of the `Cytokine Storm' in COVID-19." Journal of Infection 2020;80:6:607- 613. [CrossRef]
15. Mahmudpour, Mehdi, et al. "COVID-19 cytokine storm: The anger of inflammation." Cytokine 2020;155151. [CrossRef]
16. Liu, Jia, et al. "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro." Cell Discovery, vol. 6, no. 1, 2020. [CrossRef]
17. Schaper, Charles. "A Mechanism of Action for Hydroxychloroquine and Azithromycin to Inhibit Coronavirus Disease COVID-19." 2020. [CrossRef]
18. Chen, Jun, et al. "COVID-19 infection: the China and Italy perspectives." Cell Death & Disease, vol. 11, no. 6, 2020. [CrossRef]
19. Molina, J.M., et al. "No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection." Médecine et Maladies Infectieuses, vol. 50, no. 4, 2020, p. 384.
20. Laing, Roz, et al. "Ivermectin – Old Drug, New Tricks?" Trends in Parasitology, vol. 33, no. 6, 2017, pp. 463-472. [CrossRef]
21. Caly, Leon, et al. "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro." Antiviral Research, vol. 178, 2020, p. 104787. [CrossRef]
22. ŞİMŞEK YAVUZ, Serap, and Serhat ÜNAL. "Antiviral treatment of COVID-19." Turkish Journal of Medical Sciences, vol. 50, no. SI-1, 2020, pp. 611-619. [CrossRef]
23. Rajter, Juliana C., et al. "ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19." 2020. [CrossRef]
24. Momekov, Georgi, and DenitsaMomekova. "Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens." 2020. [CrossRef]
25. Schmith, Virginia D., et al. "The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19." 2020. [CrossRef]
26. Holmes, Natasha E., and Patrick G. Charles. "Safety and Efficacy Review of Doxycycline." Clinical Medicine Insights: Therapeutics 2009;1:471-482. [CrossRef]
27. Abegunde, Ayokunle T., et al. "Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis." Cochrane Database of Systematic Reviews, no. 1, 2016, p. CD011146. [CrossRef]
28. Sodhi, Mohit, and MahyarEtminan. "Therapeutic Potential for Tetracyclines in the Treatment of COVID‐19." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2020;40:5:487-488. [CrossRef]
29. Conforti, Claudio, et al. "Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak." Dermatologic Therapy, 2020, p. e13437 [CrossRef]
30. Gautret P, Lagier J‐C, Parola P, Hoang VT, Meddeb L, Sevestre J. Clinical and microbiological effect of a combination of Hydroxychloroquine and Azithromycin in 80 COVID‐19 patients with at least a six‐day follow up: an observational study. Mediterr‐Infect.2020:101663 https://www.mediterranee-infection. com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf
31. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline Mtalam, R Murshed, E Bhiuyan, S Saber, RfAlam, Rc Robin; Bangladesh Coll Phys Surg 2020; 38: 10-15) DOI: https://doi.org/10.3329/jbcps. v38i0.47512. [CrossRef]